What we're reading, December 4, 2015: restaurant group sues New York City over salt warnings rule; Turing CEO remains unapologetic over Daraprim price hike; and women face a higher risk of needing costly, long-term care.
Salt Warning Rule Leads to Lawsuit in NYC
The National Restaurant Association is suing New York City over a rule that would require many restaurants to post warnings on menus next to items that are high in sodium. The rule would warm diners about foods with more than the daily recommended limit of sodium. The rule took effect on Tuesday and effects restaurants with more than 15 locations nationwide, and some movie theaters and sports stadiums. Violators would be punished by a $200 fine.
Shkreli Unapologetic About Daraprim Price Hike
Despite public disapproval of the new high cost of Daraprim, Turing Pharmaceuticals CEO Martin Shkreli remains unapologetic about the increase. Although the company cut the cost of Daraprim by 50% for hospitals, insurers and some patients still have to pay the full $750 per tablet list price. STAT reported that at the Forbes Health Summit, Shkreli defended the 5000% price hike by explaining his investors expect him to “maximize profits.”
Women Face Higher Risk of Needing Costly, Long-Term Care
Long-term care is costly, but the likelihood of needing such care after the age of 65 years if you are a woman is especially high, according to a new report. While the chances an American will need a high level of long-term supports and services are approximately 50/50, those odds increase to 6 in 10 for women. They will also need it for longer. Overall, the total cost of care for women older than age 65 years far exceeds the cost for men, Forbes reported.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More